Genscript Biotech's Total Assets for the quarter that ended in Dec. 2023 was HK$26,454 Mil.
Warning Sign:
If a company builds assets at 32.5% a year, faster than its revenue growth rate of 25.8% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Genscript Biotech's average Total Assets Growth Rate was 35.20% per year.
During the past 3 years, the average Total Assets Growth Rate was 29.50% per year.
During the past 5 years, the average Total Assets Growth Rate was 32.50% per year.
During the past 10 years, Genscript Biotech's highest 3-Year average Total Assets Growth Rate was 80.90%. The lowest was 21.20%. And the median was 33.00%.
The historical data trend for Genscript Biotech's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Genscript Biotech's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genscript Biotech (HKSE:01548) Total Assets Explanation
Note:
The Net Income data used here is two times the semi-annual (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Genscript Biotech's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Genscript Biotech Total Assets Related Terms
Thank you for viewing the detailed overview of Genscript Biotech's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Genscript Biotech (HKSE:01548) Business Description
GenScript Biotech is a China-based provider of life science research services and products. Founded in 2002, it is best known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. Its business lines include life science research services and products, biologics development services under its ProBio brand, and industrial enzymes under its Bestzyme brand. Finally, it owns 57.1% of Nasdaq-listed Legend Biotech, whose key pipeline asset is a BCMA-targeting CAR-T treatment for multiple myeloma. We estimate that more than two thirds of GenScript's valuation is from its ownership stake in Legend.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01548 has been successfully added to your 